studies have been performed on SS-EO.
Therefore, the aim of the current study is to explore SS-EOs from two different regions in Lebanon SS-Bt and SS-Tl utilizing GC-MS methods and to explore their acute and subchronic antidiabetic potentials. Moreover, studying the phytochemical diversity of twenty SS-EOs established in our work and literature descriptions in order to recognize the origin of the active-chemotype s from Lebanon.
MATERIALS AND METHODS

Chemicals and Standards
All standards and chemicals used in this study have been obtained from Sigma-Aldrich Germany . All solvents have been of analytical-grade and have been used without further purification.
Plant Material
Salvia sclarea aerial parts have been collected during the same week in April 2014 from Beirut 89 m above sea level , and Taanayel 882 m above sea level .
Plant authentication has been established on reference to La Nouvelle Flore du Liban et de la Syrie 8 . Voucher specimens PS-14-8 for SS-Bt and PS14-9 for SS-Tl have been deposited in the faculty herbarium.
Extraction of EO
SS-Bt and SS-Tl EOs have been extracted for 3 h by hydro-distillation utilizing a Clevenger-apparatus, as illustrated before in the European-Pharmacopoeia 9 .
GC-MS and Quantitative Analyses
SS-Bt and SS-Tl have been analyzed utilizing GC-apparatus associated with a mass-spectrometer selective detector MSD utilizing a GC-Agilent 6890 N Network USA and a network-detector Agilent 5975 for the MSD USA . The GC has been also fitted with flame-ionization detector FID . The GC-MS system has been also equipped with Wiley Wiley, West-Sussex, England and NIST NIST 11.0, National Institute of Standards and Technology, Gaithersburg, MD library-search databases. A DB-5 MS capillary column 30 m 0.25 mm I.D., film thickness 0.10 μm has been utilized as the stationary phase. Helium has been utilized as carrier-gas 0.7 mL/min . The temperature of the column has been initially adjusted to 35 , has been increased gradually to 85 5 /min rate , has been kept for 20 min at 85 , elevated to 300 10 /min rate , and conclusively has been kept at 300 for 5 min. The sample has been diluted 1:100 v/v and then, in splitless mode, has been injected at 250 via auto-sampler. FID analysis has been done at 310 . MS-spectra have been monitored at 70 eV with 310 ion-source temperature and 320 transfer-line temperature.
Most Eo components have been GC recognized by comparing their RI values with those reported before 10 , with those of standard compounds purchased from SigmaAldrich Germany , or with MS spectra provided with the Wiley and NIST libraries 11 . Without utilizing correction factors and as reported in Table 1 , each compound relativeconcentration has been determined dependant solely on the GC peak-area.
Statistical Analysis
Utilizing Origin Pro 2016 USA , graphs of agglomerative and Heatmap hierarchical-clustering, and principle coordinate analysis PCA has been assembled that has been established on Euclidean-distance and Ward s-aggregation approach 12 . The in vivo data is presented as means S.E.M. Statistical significance was tested by one-way analysis of variance with Fisher post-hoc test. Each point represents the mean S.E.M. for 7 animals. The p-value 0.05 was designated as statistically-significant result.
Antidiabetic Activity
All animal studies were done according to the international animal ware fair act and abiding by guidelines and approval of BAU-institutional review board 2017-A-0045-P-R-0218 . Male 26-32 g Swiss Webster mice University animal house were utilized in this study. The animals were housed in their cages one day before experimentation. The animals had free-access to standard-food and water with a 12 h alternation of dark and light cycles. Mice have been alloxinated 180 mg/Kg in order to induce DM. All BGL levels have been measured via glucometers Accu-chek, Germany . Animal having BGL levels ≥ 200 mg/dL have been recognized as diabetic and have been included in the antidiabetic studies. The experimental design and dosing have been summarized in Table. 4. All tested compounds have been administered orally utilizing gavages. The acute antidiabetic effect has been measured 0, 0.5, 2 and 6 h post-EO administration. While that of the subchronic antidiabetic activity the tested compounds have been administered every other day and have been measured for 8 days post-EO administration. All doses have been compared to vehicle DMSO diabetic control groups DIA-CTRL , as reported before in literature 6 . Glibenclamide 5 mg/Kg GB has been utilized in this study as a positive control 13 . chemotypes Fig. 1 . To verify the degree of phytochemical-variations, the major components 22 was subjected to clustering studies utilizing Principal coordinate analysis PCA . Linalool LL , alpha-terpeniol AT , alpha-copaene AC , and linalyl acetate LA accounted for 86.1 of the total variability. The dispersion of chemical variability analyzed by the PCA has suggested that SS populations were clearly differentiated to the 5 chemotypes Fig. 2 . Moreover, to determine the correlation between the different regions on the basis of their EO-composition, a Heatmapcluster analysis has been performed. Heatmap-cluster analysis has shown the five main clusters Fig. 3 .
RESULTS AND DISCUSSION
EOs Phytochemical Analyses
Chemotype 1 cluster 1 has comprised the SS-Bt and the polish EOs. This cluster is characterized by relatively high linalool, alpha-terpeniol, geraniol and geranyl acetate proportions, with average of 40.2, 13.4, 6.0 and 5.2 , respectively. Chemotype 2 contains Iran, Germany and Italy I EOs, which has relatively intermediate proportions of alpha-terpeniol av. 6.3 compared to chemotypes 1. Chemotype 3 is restricted to Turkey, and it is characterized remarkably by high proportion of alpha-copaene av. 3.9 . Comparatively to other chemotypes, the relative-proportion of alpha-copaene has been found to be significantly lower. Chemotype 4 is mainly present in Italy II, which has relatively the highest alpha-terpeniol proportion 47. 4 . Relatively to other chemotypes, alpha-terpeniol has been found to be significantly lower. Chemotype 5 comprises the majority of the EOs studied, namely, Serbia, Bulgaria, Austria, Italy III and IV, China I, II and III, Brazil, Tajikistan, Russia, well as the SS-Tl from our study. Chemotype 5 is characterized by the highest linalyl acetate concentrations av. 50.4 relatively to other chemotypes. Moreover, chemotype 5 is also characterized by relatively lower levels of linalool and alpha-terpeniol, with average of 17.8 and 3.8 , respectively, when compared to chemotype 1. Thus, GC-MS analyses and phytochemical diversity studies have shown that SS-Bt is rich in Linalool LA belonging to chemotype 1, and that SS-Tl is rich in linalyl acetate LA belonging to chemotype 5.
Acute and Subchronic Antidiabetic Activities
The acute measured for 0, 0. Table 3 Table 3 . istered to diabetic mice. These compounds when tested on normal non-diabetic mice only the highest concentration of SS-Bt and LL had significant hypoglycemic activity when compared to normal non-diabetic mice control Fig. 6 . Nevertheless, these hypoglycemic effects did not reach toxic levels. Therefore, we can conclude that the tested compound possessed good safety profile within the tested doses. Volatile oils amelioration of diabetes might be due to their potential antioxidant activity 26 as they suppress glucose-induced oxidative stress 27 . Moreover, volatile oils alpha-glucosidase inhibition potentials might also contribute to their antidiabetic activity 28 . Subchronically, LL has
shown comparable results like SS-Bt, and LA has shown comparable results like SS-Tl. Thus, it could be concluded that LL and LA might be responsible also for the subchronic antidiabetic activity of SS-BT and SS-Tl, respectively. In this study, it is the first time to describe the potential acute and subchronic antidiabetic activities of SS-Bt or SS-Tl EOs.
There is an increasing need of further making clinical trials in order to fully understand Salvia sclarea antidiabetic mechanism of actions. The problem towards clinical application of Salvia sclarea might be due to several reasons. One of the problems might be the internal use of Salvia sclarea which might cause stomach lesion and ulcers; which might be solved by utilizing specially designed enteric coated capsules. The extrapolation of Salvia sclarea doses from animals to human-subjects might be also problematic in clinical trials. Another problem might be facing the Salvia sclarea clinical trials, the lack of funding organizations and infrastructure especially in developing countries; which might be resolved by encouraging non-governmental organizations in funding the promising clinical trials.
CONCLUSION
In this study, five chemotypes of S. sclarea EOs were identified by comparing twenty S. sclarea EOs established Fig. 3 Heatmap-Cluster based on metabolite profiles among the twenty S. sclarea populations. Colors in the heat map correlated to the metabolite : blue for higher level; violet for medium levels and red for lower levels. Numbers are assigned to essential oil compounds listed in Table 3 . on this work and literature descriptions. The two examined EO samples from two different regions of Lebanon, SS-Bt and SS-Tl, have shown to belong to different chemotypes, 1 and 5, respectively. Chemotypes 1 and 5 have been found to exhibit acute and subchronic antidiabetic activity due to the high percentages of LL and LA, respectively. Therefore, EOs from these two chemotypes might be used in the future as a complementary or as an alternative medicine in the management of DM, for further studies.
